Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm
This case underscores the therapeutic potential of anti-IL-6 drugs for DN-NMOSD, especially when anti-CD20 therapies fail. It highlights the heterogeneity of DN-NMOSD and the need for novel biomarkers, such as GFAP, tau, and IL-6, to better understand disease mechanisms and guide targeted treatments. A structured therapeutic approach, starting with anti-CD20 drugs and progressing to anti-IL-6 agents if ineffective, may optimize outcomes in this poorly understood condition.
Authors
- Simona Bonavita
- Elisabetta Signoriello (ORCID: https://orcid.org/0000-0001-5753-6752)
- Cinzia Coppola (ORCID: https://orcid.org/0000-0002-1125-6779)
- Mario Cirillo (ORCID: https://orcid.org/0000-0001-5350-7700)
- Giacomo Lus (ORCID: https://orcid.org/0000-0002-9457-1124)
- Giuseppe Romano (ORCID: https://orcid.org/0000-0001-7181-5627)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- University of Campania "Luigi Vanvitelli" (IT)
Publication Details
- Journal
- BMC Neurology
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s12883-025-04326-x
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00